Core Insights - Three companies, Zhipu, Tianshu Zhixin, and Jingfeng Medical-B, successfully listed on the Hong Kong Stock Exchange on January 8, 2026, with first-day gains of 13.17%, 8.44%, and 30.90% respectively [1][3][4]. Group 1: Company Performance - Zhipu, as the world's first publicly listed company focused on general artificial intelligence (AGI) foundational models, has gained significant attention from investors. The company supports over 8,000 institutional clients and approximately 80 million devices, holding a market share of 6.6% among independent AGI developers in China [5][6]. - Tianshu Zhixin specializes in general GPU products and AI computing solutions, delivering over 52,000 GPU products to more than 290 clients across various industries. The company has achieved over 900 deployments in critical sectors such as financial services and healthcare [6][7]. - Jingfeng Medical-B, established in 2017, is a leading surgical robotics company in China, recognized for its advanced multi-port and single-port laparoscopic surgical robots. The company has secured regulatory approval for its MP1000 model and has signed sales agreements for 31 units as of June 30, 2025 [7][8]. Group 2: Market Reception - The initial public offerings (IPOs) of these three companies were met with strong demand, with Zhipu and Jingfeng Medical-B experiencing over 1,000 times oversubscription in their public offerings, while Tianshu Zhixin had an oversubscription of 414.24 times [8][9]. - The strong performance of these IPOs has contributed to a positive sentiment in the Hong Kong IPO market, with expectations that upcoming listings may also perform well [4][11]. Group 3: Institutional Interest - All three companies attracted significant interest from institutional investors, with Zhipu securing a diverse base of cornerstone investors, including major public funds and private equity firms, raising a total of HKD 29.8 billion [9][10]. - Tianshu Zhixin and Jingfeng Medical-B also have backing from prominent institutions such as UBS and the Abu Dhabi Investment Authority, indicating strong confidence in their business models and growth potential [10]. Group 4: Upcoming Listings - The Hong Kong market is experiencing a surge in new listings, with additional companies set to debut shortly after the successful IPOs of Zhipu, Tianshu Zhixin, and Jingfeng Medical-B, indicating a robust pipeline for the market [11][12].

Core Viewpoint - The article discusses the recent IPOs of three companies—Zhiyu, Tianshu Zhixin, and Jingfeng Medical-B—on the Hong Kong Stock Exchange, highlighting their strong market performance and investor interest in the context of a rising trend in IPOs for 2026 [1][5][13]. Group 1: Company Performance - Zhiyu, Tianshu Zhixin, and Jingfeng Medical-B saw first-day gains of 13.17%, 8.44%, and 30.90% respectively, indicating strong market reception [2][4]. - All three companies entered the market with significant oversubscription rates, with Zhiyu and Jingfeng Medical-B exceeding 1,000 times in public offerings, while Tianshu Zhixin had a subscription rate of 414.24 times [7][11]. Group 2: Company Profiles - Zhiyu is recognized as the world's first publicly listed company focused on general artificial intelligence (AGI) foundational models, having developed a 100 billion parameter model and serving over 8,000 institutional clients [7][8]. - Tianshu Zhixin specializes in general GPU products and AI computing solutions, delivering over 52,000 GPU products to more than 290 clients across various industries [8]. - Jingfeng Medical-B is a leading surgical robotics company in China, having received regulatory approval for multiple robotic systems and achieving significant sales in the domestic market [9][10]. Group 3: Market Trends - The article notes a resurgence in IPO activity in Hong Kong, with several companies scheduled to list in early 2026, indicating a potential bullish trend for the market [14][21]. - The strong performance of newly listed companies may rekindle investor enthusiasm for IPOs, as seen with the recent gains in dark trading for companies like MINIMAX-WP and others [16][20].

Group 1 - The core offering of the company includes advanced surgical robots designed for minimally invasive procedures, with a focus on market potential in the surgical robotics sector [1][2] - The company plans to issue 27.72 million H-shares at a price of HKD 43.24 per share, aiming to raise approximately HKD 1.2 billion, with a public offering accounting for 10% of the total shares [1] - The company has received significant interest, with a reported oversubscription of 398 times the public offering amount, indicating strong demand for its shares [1] Group 2 - The product lineup includes the Precision® Multi-Port Surgical Robot and the Precision® Single-Port Surgical Robot, both of which are designed for various surgical applications across urology, gynecology, and general surgery [2] - The company has secured cornerstone investment agreements totaling USD 75 million from notable investors, including Tencent and OrbiMed Genesis, which will support the share issuance [2] - The net proceeds from the global offering are expected to be approximately HKD 1.1166 billion, with allocations planned for R&D, commercialization, capacity expansion, and potential strategic acquisitions [3]

Group 1 - The company, Jingfeng Medical, has launched an IPO with a global offering of 27.7222 million shares, including 2.7723 million shares for Hong Kong and 24.9499 million shares for international placement, along with an over-allotment option of 4.1583 million shares [1] - The share price is set at HKD 43.24, with expected fundraising of HKD 1.1166 billion if the over-allotment option is not exercised, and up to HKD 1.2892 billion if it is exercised [1] - The company is focused on the surgical robotics sector, having developed multiple models of surgical robots for minimally invasive and non-invasive surgeries since its establishment in 2017 [1] Group 2 - Jingfeng Medical's core products, the Jingfeng® multi-port and single-port surgical robots, commenced commercialization in December 2022 and December 2024, respectively, with 61 global sales agreements signed by June 30, 2025 [2] - The company has completed over 12,000 robotic-assisted clinical surgeries using the multi-port robot and over 2,000 using the single-port robot [2] - Financial data shows revenues of CNY 48.042 million for 2023, CNY 160 million for 2024, and CNY 149 million for the first half of 2025, with a nearly fourfold increase in revenue for the first half of 2025 compared to the same period in 2024 [2] - The gross profit for the first half of 2025 was CNY 93.85 million, representing a year-on-year growth of nearly 390%, making it the industry leader [2] - The company has received support from notable investors aligned with its vision for surgical robotics, including Abu Dhabi Investment Authority, UBS Asset Management, Tencent, and others [2]

Group 1 - The company plans to globally offer 27.72 million H-shares, with 2.77 million shares available in Hong Kong and 24.95 million shares for international offering, subject to reallocation and the exercise of the over-allotment option [1] - The offering price is set at HKD 43.24 per share, with a trading unit of 100 shares, and the shares are expected to start trading on January 8, 2026 [1] - The company was established in 2017 and specializes in advanced surgical robots, focusing on the design, development, and manufacturing of surgical robots [2] Group 2 - The company has entered into cornerstone investment agreements, with cornerstone investors agreeing to subscribe for a total of USD 75 million (approximately HKD 583.5 million) of the offered shares [3] - The cornerstone investors include notable entities such as Abu Dhabi Investment Authority, UBS Asset Management, and Tencent Holdings [3] - Assuming no exercise of the over-allotment option and a share price of HKD 43.24, the net proceeds from the global offering are estimated to be approximately HKD 1.1166 billion [4] Group 3 - The company plans to allocate the net proceeds as follows: approximately 23% for the development of the multi-port laparoscopic surgical robot, 19% for the single-port laparoscopic surgical robot, and 20% for the commercialization of core products [4] - Additionally, about 10% will be used to expand production capacity, 8% for other products and in-development products, and 10% for potential strategic acquisitions, investments, or collaborations in the surgical robot industry [4] - The remaining 10% will be allocated for working capital and general corporate purposes [4]

Group 1 - The company, 精锋医疗-B, plans to conduct an initial public offering (IPO) from December 30, 2025, to January 5, 2026, offering 27.72 million H-shares at a price of HKD 43.24 per share, with 10% allocated for Hong Kong and 90% for international sales [1] - The company specializes in advanced surgical robots, having developed products for minimally invasive and non-invasive surgeries, including the 精锋® multi-port laparoscopic surgical robot and the 精锋® single-port laparoscopic surgical robot [1] - The company has reported revenue growth from RMB 48 million in 2023 to RMB 160 million in 2024, with sales costs increasing from RMB 19.6 million to RMB 61.9 million during the same period [2] Group 2 - The company has not achieved profitability, recording net losses of RMB 213 million, RMB 218.5 million, RMB 133 million, and RMB 89.1 million for the years ending December 31, 2023, and 2024, and for the six months ending June 30, 2024, and 2025, respectively, primarily due to R&D expenses [2] - The company anticipates fluctuations in losses as it continues R&D, seeks regulatory approvals, and commercializes its products, with financial performance expected to vary due to uncertainties in clinical trials and commercialization success [3] - The company has secured cornerstone investment agreements totaling USD 75 million from various investors, including OrbiMed Genesis and Tencent, under certain conditions [3] Group 3 - The net proceeds from the global offering are estimated to be approximately HKD 1.1166 billion, with allocations of 42% for ongoing and planned R&D of core products, 20% for commercialization, 10% for capacity expansion, 8% for other products, and 10% for potential strategic acquisitions or investments in the surgical robot industry [4]

深圳市精鋒醫療科技股份有限公司 Shenzhen Edge Medical Co., Ltd. 股份代號 : 2675 （於中華人民共和國註冊成立的股份有限公司） 全球發售 聯席保薦人、整體協調人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 整體協調人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 重要提示 重要提示： 閣下如對本文件的任何內容有任何疑問，應尋求獨立專業意見。 Shenzhen Edge Medical Co., Ltd. 深圳市精鋒醫療科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 全球發售 | 全球發售項下的發售股份數目 | ： | 27,722,200股H股（視乎超額配股權行使 | | --- | --- | --- | | 與否而定） | | | | 香港發售股份數目 | ： | 2,772,300股H股（可予重新分配） | | 國際發售股份數目 | ： | 24,949,900股H股（可予重新分配及視乎 | | 超額配股權行使與否而定） | | | | 發售價 | ： | 每股H股43.24港元，另加1.0%經紀 | ...

Core Viewpoint - Shenzhen Precision Medical Technology Co., Ltd. (referred to as Precision Medical) is advancing in the surgical robotics sector, having successfully passed the listing hearing on the Hong Kong Stock Exchange with Morgan Stanley and Guotai Junan Securities as joint sponsors [1][3]. Company Overview - Precision Medical specializes in the design, development, and manufacturing of surgical robots, with a product lineup that includes three models at different stages of research and development, targeting the market potential of surgical robots [3]. - The company's core products include the Precision® Multi-Port Laparoscopic Surgical Robot and the Precision® Single-Port Laparoscopic Surgical Robot, along with the Precision® Bronchoscopy Robot, which is not a core product [3]. Product Details - The Precision® Multi-Port Laparoscopic Surgical Robot is designed for minimally invasive surgeries, utilizing robotic, imaging, and digital technologies across urology, gynecology, general surgery, and thoracic surgery [3]. - The Precision® Single-Port Laparoscopic Surgical Robot facilitates minimally invasive surgeries through a single small incision or natural orifice, applicable in urology, gynecology, and general surgery [3]. Market Position - According to Frost & Sullivan, Precision Medical is the first company in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots [4]. Financial Performance - For the fiscal years ending June 30, 2023, and June 30, 2024, Precision Medical reported revenues of approximately RMB 48.04 million and RMB 159.99 million, respectively, with net losses of approximately RMB 213 million and RMB 219 million for the same periods [4][6]. - The company anticipates revenues of RMB 30.25 million and RMB 149.38 million for the six months ending June 30, 2024, and 2025, respectively, with corresponding losses of RMB 132.09 million and RMB 89.09 million [4][7].